Showing results (761-770 of 1,192) with videos related to
Sort By:
Pageof 120
Pharmaceutical Statistics|June 30, 2016
Group sequential monitoring based on the weighted log-rank test statistic with the Fleming-Harrington class of weights in cancer vaccine studiesTakahiro HasegawaPharmaceutical Statistics|November 6, 2020
Estimand framework: Are we asking the right questions? A case study in the solid tumor settingMichelle Casey, Evgeny Degtyarev, María José Lechuga, et al.Pharmaceutical Statistics|November 2, 2021
Using the Bayesian detection of potential risk using inference on blinded safety data (BDRIBS) method to support the decision to refer an event for unblinded evaluationBrian Waterhouse, Alan Hartford, Saurabh Mukhopadhyay, et al.Pharmaceutical Statistics|July 12, 2022
Viewpoint: Do not resurrect the two-stage procedureStephen SennPharmaceutical Statistics|July 12, 2022
The Acute Stroke Therapy by Inhibition of Neutrophils study - Key features and impactSimon Kirby, Christy Chuang-SteinPharmaceutical Statistics|July 12, 2022
Do statisticians count? A prior and posterior viewpointMargaret Jones, Gemma HodgsonPharmaceutical Statistics|December 23, 2015
Design optimisation for pharmacokinetic modeling of a cocktail of phenotyping drugsThu Thuy Nguyen, Henri Bénech, Marcel Delaforge, et al.Pharmaceutical Statistics|October 7, 2014
An efficient analysis of covariance model for crossover thorough QT studies with period-specific pre-dose baselinesKaifeng LuPharmaceutical Statistics|March 22, 2016
Sensitivity to censored-at-random assumption in the analysis of time-to-event endpointsIlya Lipkovich, Bohdana Ratitch, Michael O'KellyPharmaceutical Statistics|April 21, 2016
Why are two mistakes not worse than one? A proposal for controlling the expected number of false claimsThomas Jaki, Alice ParryPageof 120